Crescendo Bioscience to Feature New Data on Vectra(R) DA at

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Crescendo Bioscience to Feature New Data on Vectra(R) DA at 2014 ACR Meeting

SALT LAKE CITY, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq: MYGN ), today announced that new data on Vectra ® DA will be featured at the 2014 American College of Rheumatology (ACR) Annual Meeting, Nov. 15–19, 2014, in Boston, Massachusetts.

"Vectra DA is a game changer for patients with RA because it provides clinical insights that help inform and improve clinical decisions for patients more effectively than tests like CRP or ESR," said Oscar Segurado, M.D., Chief Medical Officer of Crescendo. "The new clinical data being presented at ACR support the use of Vectra DA to assess RA disease activity and predict patient risk of joint damage."

Oral Presentations
Title: The multi-biomarker disease activity score as a predictor of radiographic progression in a registry of patients with rheumatoid arthritis.
Presenter: Eric H. Sasso
Date: November 19, 2014 9:30 a.m., Room 258 B, Presentation Number 2973
   
Title: Multi-biomarker disease activity score is associated with power Doppler ultrasound in patients with rheumatoid arthritis in low disease activity state.
Presenter: Nadine Defranoux
Date: November 19, 2014 9:45 a.m., Room 258 B, Presentation Number 2974
 
Poster Presentations
Title:  Using the multi-biomarker disease activity score as a complementary inclusion criterion for clinical trials in rheumatoid arthritis may enhance recruitment.
Presenter:  Ronald F. van Vollenhoven
Date:  November 16, 2014, 9:00-11:00 a.m., Exhibit Hall B, Presentation Number 376
   
Title:  In early rheumatoid arthritis, the multi-biomarker disease activity score at different time-points is predictive of subsequent radiographic progression.
Presenter:  Karen Hambardzumyan,
Date:  November 16, 2014, 9:00-11:00 a.m., Exhibit Hall B, Presentation Number 364
   
Title: 

In early rheumatoid arthritis patients with non-response to methotrexate monotherapy the change in multi-biomarker disease activity score is differentially associated with subsequent response to non-biological versus biological therapy.
Presenter:  Karen Hambardzumyan
Date:  November 16, 2014, 9:00-11:00 a.m., Exhibit Hall B, Presentation Number 367
   
Title:  Preliminary assessment of a multi-biomarker disease activity test for axial spondyloarthritis.
Presenter:  Walter P. Maksymowych
Date:  November 18, 2014, 9:00-11:00 a.m. Exhibit Hall B, Presentation Number 2615

About Vectra DA

Vectra DA is the only multi-biomarker blood test for rheumatoid arthritis (RA) disease activity that integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score, on a scale of 1 to 100, to help physicians make more informed treatment decisions. Vectra DA testing is performed at the Crescendo Bioscience state-of-the-art CLIA (Clinical Laboratory Improvement Amendments) facility. Test results are reported to the physician 5 to 7 days from shipping of the specimen to Crescendo Bioscience. Physicians can receive test results via standard mail, by fax or via the private web portal, VectraView. For more information on Vectra DA, please visit, www.Vectra-DA.com .

About Crescendo Bioscience

Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc., is a molecular diagnostics company dedicated to developing and commercializing quantitative blood tests for rheumatoid arthritis (RA) and other autoimmune diseases, located in South San Francisco, California. Crescendo Bioscience develops quantitative, objective, reproducible blood tests to provide rheumatologists with deeper clinical insight to help enable more effective management of patients with autoimmune and inflammatory diseases. For more information, please visit the company website at: www.CrescendoBio.com .

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com .

Myriad, the Myriad logo, BART, BRAC Analysis , Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRAC Analysis CDx, HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Vectra clinical study data to be presented at the 2014 American College of Rheumatology (ACR) Annual Meeting, November 15-19, 2014, in Boston, Massachusetts; the significant clinical value of Vectra DA, which may help doctors manage patients based on their risk of disease progression; the effectiveness of Vectra DA testing to objectively predict disease progression in patients newly diagnosed with rheumatoid arthritis (RA); and the Company's strategic directives under the captions "About Vectra DA," "About Crescendo Bioscience" and "About Myriad Genetics."  These "forward-looking statements" are management's present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to changes in the governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our Annual Report on Form 10-K for the fiscal year ended June 30, 2014, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

Media Contact: Ron Rogers (801) 584-3065 Investor Contact: Scott Gleason (801) 584-1143

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Circuit Adds Gabe Klein as Microtransit Expansion Adviser

Updated Category News Views 29

Municipal mobility is a slow, political grind, not a shiny-app contest, and Circuit’s decision to add Gabe Klein to its board looks aimed squarely at that reality. The all-electric microtransit operator has brought aboard somebody who has worked inside the machinery of city government, federal transportation policy, electrification, venture investing, and transportation...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 256

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 5

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
LRM Adds Two IND Studies Testing Injectable PDGF in Skin

Updated Category News Views 14

Under-eye medicine has a nasty habit of outrunning the evidence, which makes LRM's decision to put injectable rhPDGF-BB through more formal study worth watching. Lynch Regenerative Medicine has announced two FDA-accepted INDs for investigator-initiated clinical trials: one examining what the material does inside facial skin, the other testing it for infraorbital...

Continue Reading
COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 129

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 91

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 51

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 157

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 265

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 134

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Digital Twin Advancements in Aerospace and Defense

Updated Category News Views 435

Innovations in Digital Twin Technology for Aerospace and Defense In the fast-evolving world of technology, digital twins have emerged as a transformative asset, especially in the Aerospace and Defense sectors. Recently, the Digital Twin Consortium (DTC) has published an insightful whitepaper titled Aerospace-Defense: Digital Twin Research and Technology Gap Analysis. This...

Continue Reading
Arlo Technologies to Showcase Innovations at Upcoming Conference

Updated Category News Views 126

Arlo Technologies to Present at Piper Sandler Growth Frontiers Conference Arlo Technologies, Inc. (NYSE: ARLO), a top contender in the smart home security landscape, is gearing up to showcase its latest achievements at the Piper Sandler Growth Frontiers Conference. This esteemed event highlights innovative companies leading the way in technology, and Arlo is set to make a...

Continue Reading
Plug's Innovative Trade Desk Revolutionizes EV Market Dynamics

Updated Category News Views 833

Plug's Groundbreaking Initiatives in the Electric Vehicle Sector With a substantial seed funding of $6.7 million, Plug is making significant waves in the electric vehicle (EV) market by launching its pioneering Trade Desk. This service is tailored exclusively for EVs, setting a new precedent in the automotive industry, as it allows dealerships to assess, price, and...

Continue Reading
Exciting Winter and Spring Events at Long Island Aquarium

Updated Category News Views 215

Exciting Upcoming Events at Long Island Aquarium The Long Island Aquarium is thrilled to share its lineup of engaging events for winter and spring. Visitors can expect a variety of experiences designed to entertain the whole family. Whether you're a local resident or just visiting, there's something for everyone at this spectacular underwater haven. Culinary Delights...

Continue Reading
Bakkt Holdings, Inc. Announces Third Quarter Earnings Call

Updated Category News Views 91

Bakkt Holdings, Inc. Sets Conference Call for Q3 Earnings Bakkt Holdings, Inc. (NYSE: BKKT) is making waves as it prepares to discuss its financial results for the third quarter of 2024. The company has scheduled the earnings announcement for a date soon approaching, promising insights that will interest investors and analysts alike. Details of the Earnings Call The...

Continue Reading